MapLight Therapeutics, Inc. (MPLT) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.4x

Market Cap

$638.62M

MomentumView details →

1D Return

+4.79%

YTD Return

−21.77%

RSI (14)

43.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.4x

Market Cap

$638.62M

RSI (14)

43.6

MomentumView details →

1D Return

+4.79%

YTD Return

−21.77%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−65.99%

ROA (TTM)

−62.39%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−72.69%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−95.72%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$1.34

EPS Surprise

−39.29%

Beats (12Q)

0/12

Next Q EPS Est

−$1.17

Avg Surprise (4Q)

−752.56%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

16.52x

Quick Ratio

16.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−229.83M

Op. CF (TTM)

−174.67M

Next earningsSep 18, 2026 →

Latest newsMore news →

MapLight Therapeutics reported financial results for the second quarter ended June 30, 2026, ending the quarter with $351.3 million in cash, cash equivalents and investments.22d ago

MapLight Therapeutics reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup.22d ago

Similar companies

Bright Minds Biosciences Inc.DRUG Wuhan YZY Biopharma Co Ltd02496.HK Cutia Therapeutics02487.HK OmniAb, Inc.OABI Contineum Therapeutics, Inc. Class A Common StockCTNM Valneva SEVALN Find similar companies →

Latest newsMore news →

MapLight Therapeutics reported financial results for the second quarter ended June 30, 2026, ending the quarter with $351.3 million in cash, cash equivalents and investments.22d ago MapLight Therapeutics reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup.22d ago MapLight Therapeutics announced a private placement financing (PIPE) to raise approximately $150 million in gross proceeds from institutional and accredited investors.22d ago